🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This week marks a momentous occasion in the life of the Cancer Research UK Manchester Institute - the first research teams from the Institute move into the newest cancer research centre in town. Look out for updates starting tomorrow on our website

nature.com/articles/s4158… I am excited to share my recent publication in Nature! This is my postdoctoral work and has been published as of today. The story is about a new pan-KRAS inhibitor that can target multiple mutations in KRAS, which is a frequently mutated protein in cancer.

Why inhibit only one KRAS mutant when you can inhibit multiple KRAS alterations at the same time. Our pan-KRAS inhibitor paper is out. nature.com/articles/s4158…

Thrilled to share that our paper on Pan-KRAS inhibitors is now live nature. Inhibitors prevent activation of WT and a broad range of #KRAS mutants, while sparing HRAS+NRAS. Congrats to collaborators @boehringer and MSKCC. #PrecisionOncology OncoAlert nature.com/articles/s4158…

Dr. Martin Wermke presents data on BI 764532 - a new bispecific T cell engaged towards DLL3 and CD3 in #SCLC. Initially q3w then used a weekly step up strategy. 57 SCLC, 41 extrapulmonary small cell, 9 LCNEC. #ASCO23

Ever analyze a scRNAseq dataset and wonder if a specific cell state has been seen before? And if so, where in the human body? Under what conditions? Well, now you can use our lightning fast SCimilarity search and foundational model for that! ⚡️🔎🧬 biorxiv.org/content/10.110… (1/11)

#ESMO23 Dr. d.planchard presents an important update on FLAURA2. Phase III study of 1L osimertinib alone or with platinum + pemetrexed. Dr. Pasi Janne had presented the efficacy results at #WCLC23 that showed PFS improvement (HR 0.62 - mPFS 19.9m vs 29.4m by BICR). #LCSM

Sharing new data from #TRACERx this morning. 🟡 Pre-op #ctDNA stratifying 171 patients with untreated early stage #NSCLC studied using ultra-sensitive assay Personalis, Inc. 🟡 Adenos had 100% 5yr OS if ctDNA -ve 🟡 ctDNA +ve <80 PPM poor OS/RFS vs ctDNA -ve #LCSM #ESMO23

Wonderful summary of TRACERx latest data by Prof Mitsudomi reviewing ⁦Crispin Hiley⁩ ⁦Sonya Hessey⁩ and Wing Liu work - Clonal TMB , metastasis growth rates and Immune evasion mechanisms - thanks ⁦The Crick⁩ ⁦UCL Cancer Institute⁩ ⁦CRUK Manchester Institute⁩ Science and Innovation at Cancer Research UK⁩

🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in Nature Reviews Drug Discovery 👇. A wonderful collaboration between Klebanoff_Lab, @ND_BakerLab, Quezada Lab, and Toni Ribas. Memorial Sloan Kettering Cancer Center Parker Institute for Cancer Immunotherapy rdcu.be/dpCtp

Online Now: Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers dlvr.it/SzZvYb

🔍Understanding genetic mutations & signaling pathways is key to advancing personalized therapies for #ColorectalCancer. This study is a crucial step toward more effective treatments. Learn more: pnas.org/doi/10.1073/pn… #CancerResearch #FBXW7 #EGFRSignaling

It's been a busy day for CRUK Manchester Institute and CRUK National Biomarker Centre #PhD students at the EACR conference EACR! Victoria's work "COX-2-associated inflammation as a relapse #biomarker for early-stage lung cancer" is presented at Poster P033 #EACR2024

Together with Charles Swanton, delighted to share that our new tool, MHC Hammer - which can detect different types of HLA disruption - mutation, loss, RNA repression and alt. splicing - is now out in #NatureGenetics and available to use…nature.com/articles/s4158…... 🧵below

📺 As seen on BBC Breakfast this morning. Hear first-hand from Prof Turajlic Turajlic Lab @ The Crick, project lead of MANIFEST, and Prof Dive CRUK National Biomarker Centre discuss our vision and ambitions for the programme. 🔗bbc.co.uk/iplayer/episod… (from 07:17 | 6th Oct 2024)

Cool paper out by the Brain Metastasis Research Group showing how NK cells are crucial for efficient CD8 recruitment that enables efficacious immunotherapy to brain melanoma mets. Huge amount of work by the key authors, and was pleasure to contribute our small part. jitc.bmj.com/content/12/11/…

Here’s a closer look at #JITC article “Natural killer cells are required for the recruitment of CD8+ T cells & the efficacy of immune checkpoint blockade in melanoma brain metastases” by Christopher M Fife Brain Metastasis Research Group @SalmondLeeds Clive McKimmie (VHIT) 🦟🦠🐁 Zarnaz 🧬💻🧠 at LIMRLeeds Leeds Institute for Data Analytics

Read the full report here: jitc.bmj.com/content/12/11/… 6/6

We managed to get one last paper rdcu.be/d5gAe over the line before the new year🥂! We are pleased to share the first Nature Cell Biology paper from our lab functionally validating the role of a frequently occurring lung cancer driver, FAT1 in cancer evolution. 🧵1/13

Paper 6: #ChalabiPlot (aka Myriam Chalabi) strikes again! Results from the NICHE-2 trial initially presented ESMO - Eur. Oncology 2022 now NEJM: near 100% pathologic response with neoadjuvant nivo/ipi in dMMR colon cancer nejm.org/doi/full/10.10…